Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 19/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8475997 | 0.83 | TACR1 (0.39) | TACR1 | |
| SCHEMBL7823350 | 0.83 | TACR1 (0.39) | TACR1 | |
| SCHEMBL7120490 | 0.81 | TACR1 (0.46) | TACR1 | |
| SCHEMBL7829090 | 0.78 | TACR1 (0.62) | TACR1 | |
| SCHEMBL1512947 | 0.78 | TACR1 (0.62) | TACR1 | |
| SCHEMBL1256779 | 0.78 | TACR1 (0.62) | TACR1 | |
| Hydrochloric Acid SCHEMBL7823102 | 0.77 | TACR1 (0.61) | TACR1 | |
| Hydrochloric Acid SCHEMBL8487330 | 0.77 | TACR1 (0.61) | TACR1 | |
| SCHEMBL8120073 | 0.76 | TACR1 (0.54) | TACR1 | |
| Hydrochloric Acid SCHEMBL8147368 | 0.75 | TACR1 (0.47) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1176144-B1 | N-triazolylmethyl-piperazine derivatives as neurokinine receptor-antagonists | SOLVAY PHARM GMBH (DE) | 2003-07-09 | — | — | EP | disclosed |
| US-6407106-B1 | FOR THERAPY OF INFLAMMATORY DISTURBANCES OF THE GASTROINTESTINAL TRACT | SOLVAY PHARMACEUTICALS GMBH (DE) | 2002-06-18 | — | — | US | disclosed |
| US-20020065276-A1 | N-triazolymethyl-piperazine compounds with neurokinin-receptor antagonist activity | SOLVAY PHARMACEUTICALS GMBH (DE) | 2002-05-30 | — | — | US | disclosed |
| EP-1176144-A1 | N-triazolylmethyl-piperazine derivatives as neurokinine receptor-antagonists | Solvay Pharmaceuticals GmbH (DE) | 2002-01-30 | — | — | EP | disclosed |
| EP-0993457-A1 | AROYL-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-19 | — | — | EP | disclosed |
| WO-1998057954-A1 | AROYL-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065276-A1 | N-triazolymethyl-piperazine compounds with neurokinin-receptor antagonist activity | NPSR1, NTSR2, NTSR1 | TACR1 5/4885MEN1 1185/4885ALDH1A1 2555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.